Pulse Biosciences is no longer being valued as a leftover dermatology device name. The March realignment put the atrial fibrillation catheter at the center of the story, and the tape has treated European durability data plus faster-than-planned United States pivotal enrollment as evidence that nanosecond pulsed field ablation can matter in a market already occupied by much larger electrophysiology franchises. Product sales remain a controlled launch of the Vybrance percutaneous electrode. The second-quarter print is therefore a clinical-progress and financing quarter, not a commercial one. The investment debate is whether a still-tiny soft-tissue launch plus mid-study catheter momentum can support a multi-billion capitalization before pivotal follow-up and a real sales channel exist.
Cash finished the quarter just above one hundred million after an at-the-market sale that brought in forty seven million of net proceeds, including a sizable insider take-up. Operating cash use rose to nineteen million in the quarter as trial spend accelerated. Sequential product revenue of $434 thousand barely moved the P&L. GAAP net loss widened toward twenty five million. The balance sheet looks healthier only because equity issuance outran burn. That is the honest read: the franchise option is being funded in public, not earned from customers.
Enrollment in the NANOPULSE-AF investigational device study has already passed the halfway mark, with management targeting completion early in the fourth quarter after lifting the evaluable-patient goal. European feasibility Holter results remain the cleanest public evidence the catheter works. The next several quarters resolve whether that signal survives a larger, more heterogeneous United States pivotal cohort and whether Pulse can convert mapping-partner talks into a channel it does not currently staff. If enrollment slips or follow-up durability fades, the multiple has almost no earnings or cash-flow floor underneath it.